Seres reports positive Phase Ib trial results of SER-287 in UC patients

US-based Seres Therapeutics has reported positive topline results from a Phase Ib placebo-controlled induction trial of SER-287 in patients with mild-to-moderate ulcerative colitis (UC), who were failing current therapies.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news